Athersys Announces Partnership with Angiotech
News May 16, 2006
Athersys Inc. has announced that the Addvance division of Angiotech Pharmaceuticals, Inc. has made an investment in the company to support the development of cell-based products for treating cardiovascular disease.
The initial work will focus on applying Athersys' proprietary adult-derived stem cell product, MultiStem™, to treat patients who suffer a heart attack.
"We believe that MultiStem has the potential to significantly enhance the treatment of cardiovascular disease, and, through this partnership with Angiotech, we look forward to exploring a variety of clinical indications in the cardiovascular area, such as peripheral vascular disease and chronic ischemia," said William (B.J.) Lehmann, Executive Vice President, Corporate Development and Finance for Athersys.
As part of the collaboration, the companies will jointly manage development activities, and will share clinical development costs.
In addition, upon the achievement of certain development and commercialization milestones, Athersys will be eligible to receive milestone payments, and the companies will share profits on all developed products.
After completing pre- clinical studies, it is anticipated that human clinical trials applying MultiStem toward the treatment of myocardial infarction could begin in 2007.
Scientists have used machine learning to train computers to see parts of the cell the human eye cannot easily distinguish. Using 3D images of fluorescently labeled cells, the research team taught computers to find structures inside living cells without fluorescent labels, using only black and white images generated by an inexpensive technique known as brightfield microscopy.READ MORE
The National Institutes of Health announced the launch of a new initiative to help speed the development of cures for sickle cell disease. The Cure Sickle Cell Initiative will take advantage of the latest genetic discoveries and technological advances to move the most promising genetic-based curative therapies safely into clinical trials within five to 10 years.